Shopping Cart
Remove All
Your shopping cart is currently empty
Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $33 | - | In Stock | |
| 2 mg | $48 | - | In Stock | |
| 5 mg | $93 | - | In Stock | |
| 10 mg | $137 | - | In Stock | |
| 25 mg | $232 | - | In Stock | |
| 50 mg | $345 | - | In Stock | |
| 100 mg | $493 | - | In Stock | |
| 200 mg | $687 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $107 | - | In Stock |
| Description | Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's. |
| In vitro | Ibiglustat (L-Malic acid) (1 μM) treated Fabry disease cells are close to the physiological level in untreated WT cells in GL-3 levels. Ibiglustat (L-Malic acid) prevents additional GL-3 accumulation and ameliorates the abundant GL-3 levels in FD cardiomyocytes[4]. |
| Synonyms | Venglustat (L-Malic acid), SAR402671 (L-Malic acid), Ibiglustat L-Malic acid, GZ402671 (L-Malic acid) |
| Molecular Weight | 523.57 |
| Formula | C24H30FN3O7S |
| Cas No. | 1629063-78-0 |
| Smiles | O[C@@H](CC(O)=O)C(O)=O.CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1 |
| Relative Density. | no data available |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (171.9 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.